August 2026 · 7 min read
You have found an FBS lot that works. Growth is consistent, your assay data is clean, and reproducibility is solid. Then the lot runs out — and the next one behaves differently. Growth slows. Background rises. Your IC50 shifts by a factor of three.
This is not bad luck. It is the predictable consequence of skipping lot testing. Here is how to do it properly — before you commit to a large order.
Why FBS lots vary so much
FBS is collected from individual bovine fetuses. Each lot represents blood pooled from a defined number of animals collected during a specific season and geographic region. The growth factor composition — IGF-1, EGF, FGF-2, PDGF — varies between collection batches depending on fetal age, maternal nutrition, season, and processing conditions. Different brands of FBS have varying influences on background expression of cytokines in epithelial cells — the endogenous small molecules in FBS and ERK pathways contribute to these effects.
The practical consequence: the same cell line, the same protocol, the same assay — a different FBS lot — and your data shifts. For routine cell expansion this may be tolerable. For ELISpot, cytotoxicity IC50, hybridoma cloning efficiency, or any assay where the FBS is part of the biological environment being measured, lot-to-lot variation is a primary source of irreproducibility.
When lot testing is essential
- ELISpot and PBMC assays: endotoxin and undefined cytokines in FBS directly affect background spot counts
- Hybridoma cloning: colony formation efficiency varies 3–5 fold between lots
- AAV and viral vector production: HEK293T transfection efficiency is lot-dependent
- Stem cell and iPSC work: differentiation efficiency is highly sensitive to growth factor composition
- IVD calibrator production: any lot change requires revalidation of assay performance
- Any study lasting more than 3 months: reserve enough of a validated lot to cover the entire study
The lot testing protocol — step by step
Step 1: Request test samples
Request 50–100 mL test volumes of 2–3 candidate lots from your supplier. A reputable supplier provides these free of charge before commitment. Always include your current validated lot as a reference control — without it you cannot benchmark whether differences are lot-related or experimental variability.
Step 2: Growth curve (Days 1–4)
Seed your primary cell line at identical density (typically 5 × 10³ cells/well in 96-well or 2 × 10⁴/cm² in T-flask) in medium with 10% of each candidate lot and the reference lot. Count viable cells (trypan blue exclusion or automated counter) at 24, 48, 72 and 96 hours. Calculate population doubling time for each lot.
Pass criterion: Candidate lot doubling time within ±15% of reference lot. If a lot gives >20% slower growth — reject without further testing.
Step 3: Viability at passage
Passage cells twice in each candidate lot. Measure viability at time of passage. Target: >90% viability in all lots. A lot that produces 85% viability at passage when your reference lot gives 95% will cause progressive culture deterioration.
Step 4: Morphology check
Image cells at 48 and 96 hours in each lot. Check for: rounding, granularity, vacuolation, abnormal spreading. Subtle morphology changes often precede measurable viability or growth differences and are the fastest rejection criterion.
Step 5: Assay-specific validation
This is the step most teams skip — and it is the most important one. Run your actual assay in each candidate lot:
- ELISpot / PBMC: Run a standard antigen panel (PHA mitogen, CEF peptide pool) and measure background spot counts in unstimulated wells. Accept lots where background is <2 SFC/well and PHA response is within ±20% of reference lot.
- Cytotoxicity IC50: Run your reference compound (staurosporine or a compound with known IC50 in your lab). Accept lots where IC50 is within ±25% of reference.
- Hybridoma cloning: Run a limiting dilution cloning plate. Count colonies at Day 10. Accept lots with cloning efficiency within ±20% of reference.
- Transfection (HEK293T/AAV): Transfect with GFP reporter using your standard protocol. Measure %GFP+ cells at 48h. Accept lots within ±15% of reference.
Step 6: Reserve the validated lot
Once a lot passes all criteria — calculate your needs for 6–12 months, add 20% buffer for unexpected use, and reserve the full volume. A good supplier holds your lot without prepayment and ships in partial deliveries as needed.
How many lots should you test?
Test 2–3 candidate lots per testing round. If none pass your assay-specific criterion, request additional candidates. Never accept a lot based on growth curve alone — lots can grow cells normally while still affecting assay-specific readouts through endotoxin or cytokine contamination.
The one test most teams forget: endotoxin
The CoA endotoxin value tells you what was tested at manufacturing. It does not tell you what the lot is doing in your specific assay context. For any immune cell-based assay — PBMC, ELISpot, NK cell, macrophage — run a monocyte activation test (MAT) or simply measure IL-6 secretion in your PBMC preparation after 24h incubation in each candidate lot medium. A lot with endotoxin-mediated monocyte activation will show elevated IL-6 even without antigen stimulation. This single test eliminates most problematic lots for immunology applications.
Batch reservation at SeamlessBio
SeamlessBio holds validated FBS lots for up to 12 months without prepayment — shipping in partial deliveries on your schedule. Free test volumes available for all FBS grades. Contact info@seamlessbio.de with your cell line and application to receive matched candidate lots.
→ View FBS portfolio | → Request test volumes
Further reading:
Questions? info@seamlessbio.de | Request test samples
English 
Deutsch